Ironwood Pharmaceuticals, Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual filing, not a standalone Q4 filing; quarterly figures below are unaudited. Amounts are in U.S. dollars.
Business context
Ironwood’s principal commercial asset was linaclotide, marketed as LINZESS in the U.S. and certain other markets and as CONSTELLA in Canada and Europe. Ironwood shares U.S. LINZESS net profits or losses equally with Allergan and receives royalties and API revenue from partners in other territories. Revenue remained highly concentrated in linaclotide partnerships. In May 2018, Ironwood announced plans to separate its gastrointestinal business from its sGC programs into two public companies, Ironwood and Cyclerion, targeted for the first half of 2019.
Financial and operating highlights
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Total revenue | $346.6 million | $298.3 million |
| Collaborative arrangements revenue | $272.8 million | $265.5 million |
| Linaclotide API sales | $70.4 million | $29.7 million |
| Net loss | $282.4 million | $116.9 million |
| Net loss per share | $1.85 | $0.78 |
| Cash used in operating activities | $70.9 million | $100.8 million |
| Cash, cash equivalents and available-for-sale securities at year-end | $173.2 million | $221.4 million |
- FY revenue rose 16%, principally reflecting a $40.7 million increase in linaclotide API sales, mainly to Astellas in Japan, and higher U.S. LINZESS collaboration revenue.
- U.S. LINZESS collaboration revenue was $264.2 million, including a $29.9 million unfavorable adjustment to Ironwood’s share for revised gross-to-net reserves, primarily rebates. The filing reports underlying U.S. LINZESS demand growth.
- Research and development expense increased 12% to $166.5 million; selling, general and administrative expense increased 4% to $241.3 million.
- Operating loss was $238.9 million, or approximately 68.9% of revenue. The filing does not present a conventional product gross margin that captures the economics of its collaboration revenue.
- FY 2018 Q4 revenue was $130.7 million and net loss was $15.5 million, compared with Q4 2017 revenue of $94.2 million and net income of $12.1 million. The filing does not clearly break out Q4 revenue by source.
- Year-end current assets were $266.4 million and current liabilities $119.5 million; reported working capital excluding deferred revenue was $146.9 million. Total assets were $332.1 million and stockholders’ deficit was $196.4 million.
- Debt principal totaled approximately $485.7 million: $335.7 million of 2.25% convertible notes due 2022 and $150.0 million of 8.375% notes due 2026. The 2026 notes begin quarterly principal payments in March 2019, linked to U.S. LINZESS sales; the company estimated $47.6 million of principal due within 12 months after year-end. Cash less debt principal was approximately $312.5 million net debt.
- Operating cash use improved from 2017, while cash and cash equivalents declined to $173.2 million; there were no available-for-sale securities at year-end. Management stated that available cash was expected to fund projected operating needs for at least 12 months from issuance of the financial statements.
Material changes, outlook and risks
- Ironwood terminated its U.S. lesinurad license after test-market results did not meet expectations. It recorded a $151.8 million impairment of ZURAMPIC and DUZALLO intangibles and $15.9 million in restructuring expenses, including workforce and contract-exit costs. A $31.0 million noncash gain from reducing contingent consideration partially offset expenses.
- The company reduced its workforce during 2018; after year-end it announced a further 35-employee reduction, with estimated first-quarter 2019 charges of $3.0–$4.0 million.
- Pipeline progress included two Phase III trials of IW-3718 for persistent GERD initiated in June 2018, a Phase IIIb linaclotide trial for abdominal symptoms in IBS-C, and development of delayed-release linaclotide for IBS-D. No financial guidance was provided; management emphasized investment needs and uncertainty around profitability and positive cash flow.
- LINZESS was Ironwood’s central revenue driver, and the company warned that reliance on Allergan, partner reporting, reimbursement, competition, safety, manufacturing and supply continuity could affect results. It had no internal manufacturing or distribution capability.
- Generic challenges to LINZESS remained a material risk. Ironwood and Allergan settled with three generic manufacturers; Mylan received licenses, subject to FDA approval, beginning in 2030 for specified strengths. Litigation involving Teva and Sandoz was scheduled for trial in June 2019. The filing also disclosed a $4.0 million aggregate payment for avoidance of litigation fees and expenses under recent settlements.
- The planned separation was subject to approvals and other conditions, could be delayed or abandoned, and might not deliver expected benefits or tax-free treatment. Debt service also depends in part on Allergan-related cash flows; the 2026 notes are secured by specified payment rights and carry restrictive covenants.
- The independent auditor gave an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective as of December 31, 2018.
Important facts for investors to verify
- LINZESS U.S. prescription trends, Allergan-reported sales and expenses, and the assumptions behind gross-to-net rebates and reserves, including the $29.9 million adjustment.
- Cash runway and the timing and amount of 2026 note payments as U.S. LINZESS sales and collaboration cash flows change; also review the 2022 convertible notes and potential dilution.
- Completion, costs, tax treatment and post-separation financial position of the planned Ironwood-Cyclerion separation.
- Generic litigation and settlement terms, FDA approval timing, and the potential effects on LINZESS exclusivity and revenues.
- Results and timing of IW-3718 and linaclotide development programs, as well as risks in third-party manufacturing, reimbursement and partner execution.